Skip Nav Destination
Issues
1 October 2015
-
Cover Image
Cover Image
Geis and colleagues found that depletion of regulatory T cells (Treg) unexpectedly impaired early microadenoma formation in multiple intestinal neoplasia mice colonized by the bacterium enterotoxigenic Bacteroides fragilis (ETBF). This reduction in neoplastic growth was accompanied by a decrease in Th17 cells and IL17 production and an increase in the IFNγ-producing Th1 cell population, suggesting that Tregs modulate the balance of Th1/Th17 cells. Treg consumption of IL2 resulted in an increase in Th17 polarization and a subsequent decrease in the Th1 population following ETBF colonization, consistent with a cell-extrinsic role for Tregs in promoting Th17 differentiation. These results demonstrate that Tregs drive Th17 polarization to establish protumorigenic colitis and are necessary for the early stages of tumorigenesis in colitis-associated colorectal cancer. For details, please see the article by Geis and colleagues on page 1098. - PDF Icon PDF LinkTable of Contents
ISSN 2159-8274
EISSN 2159-8290
In This Issue
In the Spotlight
Review
Research Briefs
Author Choice
Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas
Oliver A. Zill; Claire Greene; Dragan Sebisanovic; Lai Mun Siew; Jim Leng; Mary Vu; Andrew E. Hendifar; Zhen Wang; Chloe E. Atreya; Robin K. Kelley; Katherine Van Loon; Andrew H. Ko; Margaret A. Tempero; Trever G. Bivona; Pamela N. Munster; AmirAli Talasaz; Eric A. Collisson
Author Choice
An Oncogenic NTRK Fusion in a Patient with Soft-Tissue Sarcoma with Response to the Tropomyosin-Related Kinase Inhibitor LOXO-101
Robert C. Doebele; Lara E. Davis; Aria Vaishnavi; Anh T. Le; Adriana Estrada-Bernal; Stephen Keysar; Antonio Jimeno; Marileila Varella-Garcia; Dara L. Aisner; Yali Li; Philip J. Stephens; Deborah Morosini; Brian B. Tuch; Michele Fernandes; Nisha Nanda; Jennifer A. Low
Research Articles
Detection of Enhancer-Associated Rearrangements Reveals Mechanisms of Oncogene Dysregulation in B-cell Lymphoma
Russell J.H. Ryan; Yotam Drier; Holly Whitton; M. Joel Cotton; Jasleen Kaur; Robbyn Issner; Shawn Gillespie; Charles B. Epstein; Valentina Nardi; Aliyah R. Sohani; Ephraim P. Hochberg; Bradley E. Bernstein
News in Brief
Research Watch
Apoptosis
Breast Cancer
Clinical Trials
DNA Repair
Drug Resistance
Genomics
Immunology
Immunotherapy
Leukemia
Metabolism
Sarcoma
Signaling
Structural Biology
Targeted Therapy
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.